A5011065242- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer, Lipids, and Metabolism
- Lipid metabolism and disorders
- Systemic Lupus Erythematosus Research
- Atherosclerosis and Cardiovascular Diseases
- Pharmaceutical Economics and Policy
- Pancreatitis Pathology and Treatment
- Blood Coagulation and Thrombosis Mechanisms
- Microbial Metabolism and Applications
- Cardiovascular Function and Risk Factors
- Health Systems, Economic Evaluations, Quality of Life
- Liver Disease Diagnosis and Treatment
- Platelet Disorders and Treatments
- Complement system in diseases
- Antiplatelet Therapy and Cardiovascular Diseases
- Erythrocyte Function and Pathophysiology
- Cell Adhesion Molecules Research
- Blood groups and transfusion
- Renal Diseases and Glomerulopathies
- Blood Pressure and Hypertension Studies
- Cholesterol and Lipid Metabolism
- Pregnancy and preeclampsia studies
- Diabetes and associated disorders
- Cardiovascular Disease and Adiposity
Policlinico Umberto I
2016-2025
Sapienza University of Rome
2015-2024
Medical University of Vienna
2023
Amgen (United States)
2022
Regeneron (United States)
2016-2021
University of Nis
2020
University of Belgrade
2020
Medical University of Lodz
2020
Primary Health Care
2020
New York Proton Center
2018
<h3>Importance</h3> Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder that leads to premature morbidity mortality due atherosclerotic cardiovascular disease. affects 1 in 200 250 people around the world of every race ethnicity. The lack general awareness FH among public medical community has resulted only 10% population being diagnosed adequately treated. World Health Organization recognized as a health priority 1998 during consultation meeting Geneva,...
Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin–kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels. Its effects pediatric with heterozygous familial hypercholesterolemia are not known.
Abstract Background and Aims Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disorder characterized by severely elevated LDL cholesterol (LDL-C) premature atherosclerotic cardiovascular disease. In the pivotal Phase 3 HoFH trial (NCT03399786), evinacumab significantly decreased LDL-C in patients with HoFH. This study assesses long-term safety efficacy of adult adolescent Methods this open-label, single-arm, (NCT03409744), aged ≥12 years who were evinacumab-naïve or had...
Proteins play a crucial role in metabolism, maintaining fluid and acid-base balance antibody synthesis. Dietary proteins are important nutrients classified into: 1) animal (meat, fish, poultry, eggs dairy), and, 2) plant (legumes, nuts soy). modification is one of the most lifestyle changes that has been shown to significantly decrease risk cardiovascular (CV) disease (CVD) by attenuating related factors. The CVD burden reduced optimum diet through replacement unprocessed meat with low...
Abstract Extremely high plasma triglyceride (TG) concentration is a recognized risk factor for acute pancreatitis (AP). In order to evaluate the therapeutic efficacy of plasma‐exchange plasmapheresis in treating patients with severe hypertriglyceridemia (sHTG), 17 who had not responded conventional medical therapy (fat‐free diet plus pharmaceutical interventions) were referred exchange (TPE) multicenter frame case series study. Two hundred seventeen TPE sessions performed, and ongoing five...
Hypercholesterolaemia is amongst the most common conditions encountered in medical profession.It remains one of key modifiable cardiovascular risk factors and there have been recent advances stratification methods treatment options available.In this review, we provide a background into hypercholesterolaemia for non-specialists consider merits different assessment tools available.We also detailed considerations as to: i) when to start treatment, ii) what targets aim iii) role low density...
Mutations in the genes for low-density lipoprotein receptor (LDLR), apolipoprotein B, and proprotein convertase subtilisin/kexin type 9 have been reported to cause heterozygous homozygous familial hypercholesterolemia (FH).The objective is examine influence of double heterozygous, compound or mutations underlying FH on efficacy alirocumab.Patients from 6 alirocumab trials with elevated cholesterol (LDL-C) diagnosis were sequenced LDLR, 9, LDLR adaptor protein 1 (LDLRAP1), signal-transducing...
Abstract Aims Children with heterozygous familial hypercholesterolaemia (HeFH) show greater carotid intima-media thickness (cIMT). Evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibody, substantially reduced LDL cholesterol (LDL-C) in children HeFH. We investigated evolocumab’s effect on cIMT progression. Methods and results HAUSER-RCT was randomized, placebo-controlled trial. One hundred fifty-seven paediatric patients FH (age: 10–17 years) LDL-C &gt;...